Literature DB >> 35021095

Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells.

Evan R Abt1, Thuc M Le1, Amanda M Dann2, Joseph R Capri1, Soumya Poddar1, Vincent Lok1, Luyi Li2, Keke Liang3, Amanda L Creech1, Khalid Rashid1, Woosuk Kim1, Nanping Wu2, Jing Cui4, Arthur Cho5, Hailey Rose Lee1, Ethan W Rosser1, Jason M Link6, Johannes Czernin1, Ting-Ting Wu7, Robert Damoiseaux8, David W Dawson9, Timothy R Donahue10, Caius G Radu11.   

Abstract

We determine that type I interferon (IFN) response biomarkers are enriched in a subset of pancreatic ductal adenocarcinoma (PDAC) tumors; however, actionable vulnerabilities associated with IFN signaling have not been systematically defined. Integration of a phosphoproteomic analysis and a chemical genomics synergy screen reveals that IFN activates the replication stress response kinase ataxia telangiectasia and Rad3-related protein (ATR) in PDAC cells and sensitizes them to ATR inhibitors. IFN triggers cell-cycle arrest in S-phase, which is accompanied by nucleotide pool insufficiency and nucleoside efflux. In combination with IFN, ATR inhibitors induce lethal DNA damage and downregulate nucleotide biosynthesis. ATR inhibition limits the growth of PDAC tumors in which IFN signaling is driven by stimulator of interferon genes (STING). These results identify a cross talk between IFN, DNA replication stress response networks, and nucleotide metabolism while providing the rationale for targeted therapeutic interventions that leverage IFN signaling in tumors.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  STING; interferon; nucleotide metabolism; pancreas cancer; replication stress

Mesh:

Substances:

Year:  2022        PMID: 35021095      PMCID: PMC8893345          DOI: 10.1016/j.celrep.2021.110236

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  66 in total

Review 1.  Cytosolic DNA Sensing in Organismal Tumor Control.

Authors:  Claire Vanpouille-Box; Sandra Demaria; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Cancer Cell       Date:  2018-06-28       Impact factor: 31.743

2.  Regulation of E2Fs and senescence by PML nuclear bodies.

Authors:  Mathieu Vernier; Véronique Bourdeau; Marie-France Gaumont-Leclerc; Olga Moiseeva; Virginie Bégin; Fred Saad; Anne-Marie Mes-Masson; Gerardo Ferbeyre
Journal:  Genes Dev       Date:  2011-01-01       Impact factor: 11.361

3.  Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA.

Authors:  Zhikuan Zhang; Umeharu Ohto; Takuma Shibata; Elena Krayukhina; Masato Taoka; Yoshio Yamauchi; Hiromi Tanji; Toshiaki Isobe; Susumu Uchiyama; Kensuke Miyake; Toshiyuki Shimizu
Journal:  Immunity       Date:  2016-10-11       Impact factor: 31.745

4.  Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.

Authors:  Simona Dalin; Mark R Sullivan; Allison N Lau; Beatrice Grauman-Boss; Helen S Mueller; Emanuel Kreidl; Silvia Fenoglio; Alba Luengo; Jacqueline A Lees; Matthew G Vander Heiden; Douglas A Lauffenburger; Michael T Hemann
Journal:  Cancer Res       Date:  2019-09-04       Impact factor: 12.701

5.  MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data.

Authors:  Jianguo Xia; David S Wishart
Journal:  Nucleic Acids Res       Date:  2010-05-10       Impact factor: 16.971

6.  Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.

Authors:  Jason R Baird; David Friedman; Benjamin Cottam; Thomas W Dubensky; David B Kanne; Shelly Bambina; Keith Bahjat; Marka R Crittenden; Michael J Gough
Journal:  Cancer Res       Date:  2015-11-13       Impact factor: 12.701

7.  Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.

Authors:  Yong-Wei Zhang; Tamara L Jones; Scott E Martin; Natasha J Caplen; Yves Pommier
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

Review 8.  Pancreatic cancer.

Authors:  Terumi Kamisawa; Laura D Wood; Takao Itoi; Kyoichi Takaori
Journal:  Lancet       Date:  2016-01-30       Impact factor: 79.321

9.  Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair.

Authors:  Vincenzo D'Angiolella; Valerio Donato; Frances M Forrester; Yeon-Tae Jeong; Claudia Pellacani; Yasusei Kudo; Anita Saraf; Laurence Florens; Michael P Washburn; Michele Pagano
Journal:  Cell       Date:  2012-05-25       Impact factor: 41.582

10.  Widespread parainflammation in human cancer.

Authors:  Dvir Aran; Audrey Lasry; Adar Zinger; Moshe Biton; Eli Pikarsky; Asaf Hellman; Atul J Butte; Yinon Ben-Neriah
Journal:  Genome Biol       Date:  2016-07-08       Impact factor: 13.583

View more
  3 in total

1.  Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity.

Authors:  Evan R Abt; Khalid Rashid; Thuc M Le; Suwen Li; Hailey R Lee; Vincent Lok; Luyi Li; Amanda L Creech; Amanda N Labora; Hanna K Mandl; Alex K Lam; Arthur Cho; Valerie Rezek; Nanping Wu; Gabriel Abril-Rodriguez; Ethan W Rosser; Steven D Mittelman; Willy Hugo; Thomas Mehrling; Shanta Bantia; Antoni Ribas; Timothy R Donahue; Gay M Crooks; Ting-Ting Wu; Caius G Radu
Journal:  J Clin Invest       Date:  2022-08-15       Impact factor: 19.456

2.  Targeting E2F Sensitizes Prostate Cancer Cells to Drug-Induced Replication Stress by Promoting Unscheduled CDK1 Activity.

Authors:  Mohaddase Hamidi; Ainhoa Eriz; Jone Mitxelena; Larraitz Fernandez-Ares; Igor Aurrekoetxea; Patricia Aspichueta; Ainhoa Iglesias-Ara; Ana M Zubiaga
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

Review 3.  Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.

Authors:  Yu-Huei Liu; Chun-Mei Hu; Yuan-Sheng Hsu; Wen-Hwa Lee
Journal:  Cell Death Dis       Date:  2022-09-24       Impact factor: 9.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.